Ralph E. Parchment
About
In The Last Decade
Ralph E. Parchment
178 papers receiving 4.2k citations
Peers
Comparison fields: 5 of 139
- Molecular Biology 2.3k
- Oncology 1.8k
- Cancer Research 729
- Immunology 478
- Pulmonary and Respiratory Medicine 430
Countries citing papers authored by Ralph E. Parchment
This map shows the geographic impact of Ralph E. Parchment's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph E. Parchment with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph E. Parchment more than expected).
Fields of papers citing papers by Ralph E. Parchment
This network shows the impact of papers produced by Ralph E. Parchment. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph E. Parchment. The network helps show where Ralph E. Parchment may publish in the future.
Co-authorship network of co-authors of Ralph E. Parchment
This figure shows the co-authorship network connecting the top 25 collaborators of Ralph E. Parchment. A scholar is included among the top collaborators of Ralph E. Parchment based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph E. Parchment. Ralph E. Parchment is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 3 | |
| 5 | 12 | |
| 6 | 7 | |
| 7 | 24 | |
| 8 | 19 | |
| 9 | 155 | |
| 10 | 60 | |
| 11 | 56 | |
| 12 | 75 | |
| 13 | 126 | |
| 14 | Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP | 6 |
| 15 | Development and preclinical modeling of a topoisomerase I pharmacodynamic immunoassay for use in clinical trials | 1 |
| 16 | Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors | 1 |
| 17 | A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage | 1 |
| 18 | Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX | 1 |
| 19 | The selective PARP inhibitor, CEP-8983 exhibits significant chemosensitization in combination with TMZ and SN38 against chemoresistant tumor cell lines and xenografts | 1 |
| 20 | Haematotoxicity of mycotoxins | 22 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.